[go: up one dir, main page]

WO1997007819B1 - Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter - Google Patents

Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter

Info

Publication number
WO1997007819B1
WO1997007819B1 PCT/EP1996/003733 EP9603733W WO9707819B1 WO 1997007819 B1 WO1997007819 B1 WO 1997007819B1 EP 9603733 W EP9603733 W EP 9603733W WO 9707819 B1 WO9707819 B1 WO 9707819B1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
cells
antigen
receptor
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1996/003733
Other languages
German (de)
English (en)
Other versions
WO1997007819A1 (fr
Filing date
Publication date
Priority claimed from DE19531346A external-priority patent/DE19531346A1/de
Application filed filed Critical
Priority to DK96929318T priority Critical patent/DK0845998T3/da
Priority to AT96929318T priority patent/ATE208630T1/de
Priority to US09/029,369 priority patent/US6294167B1/en
Priority to EP96929318A priority patent/EP0845998B1/fr
Priority to DE59608213T priority patent/DE59608213D1/de
Publication of WO1997007819A1 publication Critical patent/WO1997007819A1/fr
Publication of WO1997007819B1 publication Critical patent/WO1997007819B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

L'invention concerne des médicaments contenant des anticorps présentant au moins une spécificité, qui identifient l'antigène du MCHII d'un patient à traiter. L'invention concerne en outre des anticorps présentant deux spécificités ou plus, qui identifient l'antigène MCHII d'un patient, ainsi que des compositions diagnostiques contenant lesdits anticorps.
PCT/EP1996/003733 1995-08-25 1996-08-23 Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter Ceased WO1997007819A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DK96929318T DK0845998T3 (da) 1995-08-25 1996-08-23 Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
AT96929318T ATE208630T1 (de) 1995-08-25 1996-08-23 Arzneimittel zur immuntherapie, enthaltend antikörper, die spezifisch das mhcii-antigen eines zu behandelnden patienten erkennen
US09/029,369 US6294167B1 (en) 1995-08-25 1996-08-23 Pharmaceutical compositions for immunotherapy containing antibodies which specifically recognize the MHCII antigen of a patient to be treated
EP96929318A EP0845998B1 (fr) 1995-08-25 1996-08-23 Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter
DE59608213T DE59608213D1 (de) 1995-08-25 1996-08-23 Arzneimittel zur immuntherapie, enthaltend antikörper, die spezifisch das mhcii-antigen eines zu behandelnden patienten erkennen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19531346A DE19531346A1 (de) 1995-08-25 1995-08-25 Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen
DE19531346.1 1995-08-25

Publications (2)

Publication Number Publication Date
WO1997007819A1 WO1997007819A1 (fr) 1997-03-06
WO1997007819B1 true WO1997007819B1 (fr) 1997-05-15

Family

ID=7770409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/003733 Ceased WO1997007819A1 (fr) 1995-08-25 1996-08-23 Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter

Country Status (8)

Country Link
US (1) US6294167B1 (fr)
EP (1) EP0845998B1 (fr)
AT (1) ATE208630T1 (fr)
DE (2) DE19531346A1 (fr)
DK (1) DK0845998T3 (fr)
ES (1) ES2164914T3 (fr)
PT (1) PT845998E (fr)
WO (1) WO1997007819A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8296098A (en) * 1997-07-08 1999-02-08 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
DE19937264A1 (de) * 1999-08-06 2001-02-15 Deutsches Krebsforsch F¶v¶-Antikörper-Konstrukte
AU1290001A (en) * 1999-11-18 2001-05-30 Oxford Biomedica (Uk) Limited Antibodies
AU2002340167A1 (en) * 2001-10-11 2003-06-17 Protein Design Labs Inc. Anti-hla-dr antibodies and the methods of using thereof
DE10261223A1 (de) * 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
CA2606081C (fr) 2005-04-26 2013-09-17 Markus M. Heiss Combinaison d'anticorps et de glucocorticoides destinee au traitement du cancer
GB0509318D0 (en) * 2005-05-06 2005-06-15 Chiron Srl TCR-independent activation of T cells
GB0512225D0 (en) * 2005-06-16 2005-07-27 Univ Sheffield Immunoglobulin molecules
EP1820513A1 (fr) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction des cellules tumorales exprimant à un niveau bas ou moyen des antigènes cibles associés aux tumeurs, par des anticorps trifonctionels bispécifiques
US7862813B2 (en) * 2006-07-29 2011-01-04 Bjork Jr Robert Lamar Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug
GB0803076D0 (en) * 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
EP2241576A1 (fr) 2009-04-17 2010-10-20 Trion Pharma Gmbh Utilisation des anticorps bispécifiques trifonctionnels pour le traitement des tumeurs associées aux cellules souches de cancer CD133+/EpCAM+
HUE054034T2 (hu) * 2014-03-13 2021-08-30 Univ Basel Mielin asszociált glikoprotein elleni IgM antitestekhez kapcsódó szénhidrát ligandumok
WO2018099539A1 (fr) 2016-11-29 2018-06-07 Horst Lindhofer Combinaison d'anticorps multifonctionnels de redirection de lymphocytes (t) avec des modulateurs de point de contrôle immunitaires et leurs utilisations
EP3579848B1 (fr) 2017-02-08 2024-10-30 Dragonfly Therapeutics, Inc. Protéines de fixation multi-spécifiques destinées à l'activation de cellules tueuses naturelles et leurs utilisations thérapeutiques pour traiter le cancer
AU2018220736B2 (en) 2017-02-20 2024-10-24 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
WO2019157366A1 (fr) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Domaines variables d'anticorps ciblant le récepteur nkg2d
PE20210375A1 (es) 2018-02-08 2021-03-02 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
WO2019164930A1 (fr) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Protéines de liaison multi-spécifiques qui se lient à cd33, nkg2d et cd16, et procédés d'utilisation
KR20210043602A (ko) 2018-08-08 2021-04-21 드래곤플라이 쎄라퓨틱스, 인크. Bcma, nkg2d 및 cd16에 결합하는 다중특이성 결합 단백질 및 이의 사용 방법
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
JP7482363B2 (ja) 2018-08-08 2024-05-14 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質
CN115836088A (zh) 2020-05-06 2023-03-21 蜻蜓疗法股份有限公司 结合nkg2d、cd16和clec12a的蛋白质
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068790B1 (fr) * 1981-06-25 1986-02-26 The Board Of Trustees Of The Leland Stanford Junior University Méthode immunothérapeutique allèle spécifique et forme de dosage
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies

Similar Documents

Publication Publication Date Title
WO1997007819B1 (fr) Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter
Mason et al. LGL-1: a non-polymorphic antigen expressed on a major population of mouse natural killer cells.
Weiss et al. Requirement for the coexpression of T3 and the T cell antigen receptor on a malignant human T cell line.
Reinherz et al. Antibody directed at a surface structure inhibits cytolytic but not suppressor function of human T lymphocytes
US6294167B1 (en) Pharmaceutical compositions for immunotherapy containing antibodies which specifically recognize the MHCII antigen of a patient to be treated
EP0403156B1 (fr) Anticorps monoclonaux améliorés contre le récepteur alpha/bêta des cellules T humaines, leur production et leur utilisation
US5777084A (en) Antibody BV10A4H2 specific for human FLT3/FLK2 receptor and mybridoma
Bonnefoy et al. The low-affinity receptor for IgE (CD23) on B lymphocytes is spatially associated with HLA-DR antigens.
KR100426113B1 (ko) 티(t)-세포항원,및티(t)-세포매개증상의진단및치료에있어서의이의용도
US5885573A (en) Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
FI117900B (fi) Menetelmä solun valmistamiseksi, joka ilmentää soluvälitteisen immuuniteetin uudelleensuuntaavia reseptorikimeeroja, ja niitä koodaava DNA ja vektori
Schiller et al. CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells
Spertini et al. Induction of human T cell proliferation by a monoclonal antibody to CD5.
Pauza et al. Unusual patterns of immunoglobulin gene rearrangement and expression during human B cell ontogeny: human B cells can simultaneously express cell surface kappa and lambda light chains.
JPH0223156B2 (fr)
Todd III et al. A monoclonal antibody that blocks class II histocompatibility-related immune interactions
Saal et al. Lymphocytes with T-cell markers cooperate with IgG antibodies in the lysis of human tumour cells
EP0241811B1 (fr) Anticorps monoclonal contre le récepteur de l'interleukine-2 humaine
FI75598C (fi) Foerfarande foer framstaellning av en monoklonal antikropp mot en maensklig tymocytantigen medelst en ny hybridcellinje.
Alvarez-Vallina et al. Delimitation of the proliferative stages in the human thymus indicates that cell expansion occurs before the expression of CD3 (T cell receptor)
US6156882A (en) Antibody 4G8B4B12
Basel Targeting and activation of cytotoxic lymphocytes
WO1997008205B1 (fr) Anticorps presentant deux specificites ou plus pour l'elimination specifique de cellules in vivo
Hogarth et al. A monoclonal antibody detecting the Ly-9.2 (Lgp 100) cell-membrane alloantigen
Shearman et al. Construction, expression, and biologic activity of murine/human chimeric antibodies with specificity for the human alpha/beta T cell receptor.